2nd Innovation in Obesity Therapeutics Summit

The obesity therapeutics landscape is undergoing a radical expansion, fueled by groundbreaking late-stage trials for Novo Nordisk's amycretin and Metsera's exciting early data for its amylin-targeting shot. Underscored by new insights into Eli Lilly's tirzepatide's cardiovascular benefits, the field is witnessing a paradigm shift beyond GLP-1s to novel mechanisms, combination therapies, and oral formulations. This new era of innovation promises wider accessibility and improved patient outcomes, making the 2nd Innovation in Obesity Therapeutics Summit the essential forum for accelerating the next wave of treatment.

This year, we're diving deep into game-changing potential of novel mechanisms of action, muscle-preserving strategies, and multi-agonist therapies. Hear from the titans of the pharmaceutical industry, including Novo Nordisk, Eli Lilly and Boehringer Ingelheim, as well as innovative biotechs like Veru, Supercede Therapeutics, and Rivus Pharmaceuticals, who will share their groundbreaking research and strategies. The pressure is on to continue work on developing best-in-class treatments that transform patient lives.

Don't miss this pivotal opportunity to network with 60+ leading scientists and drug development experts in the field of obesity, forge crucial collaborations, and be part of the solution. The future of obesity therapeutics is being written now - be a part of it!


URLs:
Website: https://go.evvnt.com/3203598-0?pid=2874
Brochure: https://go.evvnt.com/3203598-2?pid=2874

Category: Conferences | Science, Health and Medicine | Pharmaceuticals

Prices:
Drug Developer Pricing - Conference + Pre-Conference Focus Day: USD 4197.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Academic Pricing - Conference + Pre-Conference Focus Day: USD 3597.00,
Academic Pricing - Conference Only: USD 2599.00,
Service and Solution Pricing - Conference + Pre-Conference Focus Day: USD 5097.00,
Service and Solution Pricing - Conference Only: USD 3699.00

Speakers: Anton Pekcec, Director, Cardiometabolic Diseases Research, Boehringer Ingelheim, Julia Dunn, Executive Director, Medical, Eli Lilly, Martin Marro, Executive Director, Cell Pharmacology, Obesity and Complications, Eli Lilly, Sara Gry, Vienberg Director, Scientific Strategy, Novo Nordisk, Cory Schwartz, Director, Research and Early Development, iBio, David Bearss, President, Chief Executive Officer and Co-Founder, Halia Therapeutics, Gary Barnette, Chief Scientific Officer, Veru Inc., Gordon Foulkes, Chief Executive Officer, Lipidio Pharmaceuticals, lan Zipkin, Chief Executive Officer, Supercede Therapeutics, Inc., Jeremiah Bearss, Chief Medical Officer, Biolexis Therapeutics, John Mayer, Chief Scientific Officer, Ambrosia Biosciences, Laurent Audoly, Chief Executive Officer, Prive Bio, Raj Reddy, Chief Executive Officer, Canary Global, Mitchell Steiner, Chairman, Chief Executive Officer and President, Veru Inc, Robert Schott, Chief Medical Officer, Rivus Pharmaceuticals Inc., Tom Hardy, Chief Medical Officer, Adipo Therapeutics, David Tingley, Founder, Olio Labs, Patrice Lee, Head of R and D and Pharmacology, Ambrosia Biosciences, Marco Falasca, Professor Biochemistry, Medicine and Surgery University of Parma